Special edition in Croatian: Chapter 13 Volume 059 P. 128 - 134
English
Select your language
Official EU languages:
Access to European Union law
EUR-Lex
Access to European Union law
This document is an excerpt from the EUR-Lex website
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Need more search options? Use the
Advanced search
Document 32010D0030
2010/30/: Commission Decision of 9 December 2009 amending the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2009) 9703) (Text with EEA relevance)
2010/30/: Commission Decision of 9 December 2009 amending the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2009) 9703) (Text with EEA relevance)
2010/30/: Commission Decision of 9 December 2009 amending the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products (notified under document C(2009) 9703) (Text with EEA relevance)
OJ L 12, 19.1.2010, p. 14–20
(BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV) This document has been published in a special edition(s)
(HR)
In force
Language
HTML
PDF
Official Journal
|
19.1.2010 |
EN |
Official Journal of the European Union |
L 12/14 |
COMMISSION DECISION
of 9 December 2009
amending the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products
(notified under document C(2009) 9703)
(Text with EEA relevance)
(2010/30/EU)
THE EUROPEAN COMMISSION,
Having regard to the Treaty on European Union and to the Treaty on the Functioning of the European Union,
Having regard to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (1), and in particular Article 16(f) thereof,
Having regard to the opinions of the European Medicines Agency, formulated on 10 January 2008 and 6 March 2008 by the Committee for Herbal Medicinal Products,
Whereas:
|
(1) |
‘Eleutherococcus senticosus (Rupr. et Maxim.) Maxim’ and ‘Echinacea purpurea (L.) Moench’ comply with the requirements set out in Directive 2001/83/EC. ‘Eleutherococcus senticosus (Rupr. et Maxim.) Maxim’ and ‘Echinacea purpurea (L.) Moench’ can be considered as herbal substances, herbal preparations or combinations thereof. |
|
(2) |
It is therefore appropriate to include ‘Eleutherococcus senticosus (Rupr. et Maxim.) Maxim’ and ‘Echinacea purpurea (L.) Moench’ in the list of herbal substances, preparations and combinations thereof for use in traditional herbal medicinal products established in Annex I to Commission Decision 2008/911/EC (2). |
|
(3) |
Decision 2008/911/EC should therefore be amended accordingly. |
|
(4) |
The measures provided for in this Decision are in accordance with the opinion of the Standing Committee on Medicinal Products for Human Use, |
HAS ADOPTED THIS DECISION:
Article 1
Decision 2008/911/EC is amended as follows:
|
1. |
Annex I is amended in accordance with Annex I to this Decision; |
|
2. |
Annex II is amended in accordance with Annex II to this Decision. |
Article 2
This Decision is addressed to the Member States.
Done at Brussels, 9 December 2009.
For the Commission
Günter VERHEUGEN
Vice-President
ANNEX I
In Annex I to Decision 2008/911/EC, the following two substances are inserted after ‘ Calendula officinalis L.’:
|
— |
‘ Echinacea purpurea (L.) Moench’ |
|
— |
‘ Eleutherococcus senticosus (Rupr. et Maxim.) Maxim’ |
ANNEX II
In Annex II to Decision 2008/911/EC, the following is inserted after the entry relating to ‘ Calendula officinalis L’:
‘ COMMUNITY LIST ENTRY ON ECHINACEA PURPUREA (L.) MOENCH, HERBA RECENS
Scientific name of the plant
Echinacea purpurea (L.) Moench
Botanical family
Asteraceae
Herbal substance
Purple coneflower herb
Common name in all EU official languages of herbal substance
|
|
BG (bălgarski): пурпурна ехинацея, пресен стрък |
|
|
CS (čeština): čerstvá nať třapatky nachové |
|
|
DA (dansk): Purpursolhat, frisk urt |
|
|
DE (Deutsch): Purpursonnenhutkraut, frisch |
|
|
EL (elliniká): Πόα Εχινάκεας της πορφυράς |
|
|
EN (English): purple coneflower herb |
|
|
ES (español): Equinácea purpúrea, partes aéreas incluidas sumidades floridas |
|
|
ET (eesti keel): punane siilkübar |
|
|
FI (suomi): kaunopunahattu, tuore verso |
|
|
FR (français): parties aériennes fraîches d’échinacée pourpre |
|
|
HU (magyar): bíbor kasvirág virágos hajtása |
|
|
IT (italiano): Echinacea purpurea, pianta fresca |
|
|
LT (lietuvių kalba): rausvažiedžių ežiuolių žolė |
|
|
LV (latviešu valoda): purpursarkanās ehinacejas laksti |
|
|
MT (malti): Echinacea Vjola |
|
|
NL (nederlands): rood zonnehoedkruid |
|
|
PL (polski): jeżówka purpurowa, świeże ziele |
|
|
PT (português): Equinácea, partes aéreas floridas |
|
|
RO (română): iarbã proaspãtã de Echinacea, pãlãria soarelui |
|
|
SK (slovenčina): echinacea purpurová, čerstvá vňať |
|
|
SL (slovenščina): sveža zel škrlatne ehinaceje |
|
|
SV (svenska): röd solhatt, färsk ört |
|
|
IS (íslenska): Sólhattur |
|
|
NO (norsk): Rød solhatt |
Herbal preparation(s)
Expressed juice and dried expressed juice from fresh flowering aerial parts.
European Pharmacopoeia monograph reference
N/A
Indication(s)
Traditional herbal medicinal product for treatment of small superficial wounds.
The product is a traditional herbal medicinal product for use in a specified indication exclusively based on long-standing use.
Type of tradition
European.
Specified strength
10 to 20 g/100 g of expressed juice or equivalent amount of dried expressed juice in liquid or semi-solid dosage forms.
Specified posology
Adolescents over the age of 12 years, adults, elderly
Small amount of ointment is applied on the affected area 2-3 times a day.
The use in children under 12 years of age is not recommended (see below “Special warnings and precautions for use”).
Route of administration
Cutaneous use.
Duration of use or any restrictions on the duration of use
Do not use the medicinal product for more than 1 week.
If the symptoms persist during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted.
Any other information necessary for the safe use
Contra-indications
Hypersensitivity to the active substance or to plants of the Asteraceae (Compositae) family.
Special warnings and precautions for use
If signs of skin infection are observed, medical advice should be sought.
The use in children below 12 years of age is not recommended because a safe use has not been sufficiently documented.
Interactions with other medicinal products and other forms of interaction
None reported.
Pregnancy and lactation
There are no data on cutaneous use during pregnancy or lactation.
Products containing Echinacea should not be applied to the breast of breastfeeding women.
Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed.
Undesirable effects
Hypersensitive reactions (local rash, contact dermatitis, eczema and angioedema of the lips) may occur.
The frequency is not known.
If other adverse reactions not mentioned above occur, a doctor or a qualified healthcare practitioner should be consulted.
Overdose
No case of overdose has been reported.
COMMUNITY LIST ENTRY ON ELEUTHEROCOCCUS SENTICOSUS (RUPR. ET MAXIM.) MAXIM., RADIX
Scientific name of the plant
Eleutherococcus senticosus (Rupr. et Maxim.) Maxim.
Botanical family
Araliaceae
Herbal substance
Eleutherococcus root
Common name in all EU official languages of herbal substance
|
|
BG (bălgarski): елеутерокок, корен |
|
|
CS (čeština): eleuterokokový kořen |
|
|
DA (dansk): Russisk rod |
|
|
DE (Deutsch): Taigawurzel |
|
|
EL (elliniká): Pίζα Eλευθεροκόκκου |
|
|
EN (English): Eleutherococcus root |
|
|
ES (español): Eleuterococo, raíz de |
|
|
ET (eesti keel): eleuterokokijuur |
|
|
FI (suomi): venäjänjuuren juuri |
|
|
FR (français): racine d’éleuthérocoque (racine de ginseng sibérien) |
|
|
HU (magyar): Szibériai ginszeng gyökér (tajga gyökér) |
|
|
IT (italiano): Eleuterococco radice |
|
|
LT (lietuvių kalba): Eleuterokokų šaknys |
|
|
LV (latviešu valoda): Eleiterokoka sakne |
|
|
MT (malti): Għerq ta’ l-elewterokokku |
|
|
NL (nederlands): Russische ginsengwortel |
|
|
PL (polski): korzeń eleuterokoka |
|
|
PT (português): Raiz de Ginseng Siberiano |
|
|
RO (română): Rădăcină de ginseng siberian |
|
|
SK (slovenčina): Všehojovcový koreň |
|
|
SL (slovenščina): korenina elevterokoka |
|
|
SV (svenska): Rysk rot |
|
|
IS (íslenska): Síberíu ginseng, rót |
|
|
NO (norsk): Russisk rot |
Herbal preparation(s)
Comminuted herbal substance for preparation of a herbal tea
Liquid extract (1:1, ethanol 30-40 % v/v)
Dry extract (13-25: 1, ethanol 28-40 % v/v)
Dry extract (17-30: 1, ethanol 70 % v/v)
Dry aqueous extract (15-17:1)
Tincture (1:5, ethanol 40 % v/v)
European Pharmacopoeia monograph reference
Eleutherococcus — Eleutherococci radix (ref.: 01/2008: 1419 corrected 6.0)
Indication(s)
Traditional herbal medicinal product for symptoms of asthenia such as fatigue and weakness.
The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.
Type of tradition
Chinese, European.
Specified strength
Not applicable.
Specified posology
Adolescents over 12 years of age, adults, elderly
Herbal preparations.
Daily dose.
Comminuted herbal substance as herbal tea: 0,5-4 g.
Tea preparation: 0,5 to 4 g of comminuted herbal substance for infusion in 150 ml of boiling water.
Dosage frequency: 150 ml of tea infusion should be divided in one to three doses taken during the day.
Liquid extract: 2-3 ml.
Dry extracts (ethanol 28-70 % v/v) corresponding to 0,5-4 g dried root.
Dry aqueous extract (15-17:1): 90-180 mg.
Tincture: 10-15 ml.
The daily dose can be taken in one to three doses.
The use is not recommended in children under 12 years of age (see below “Special warnings and precautions for use”).
Route of administration
Oral use.
Duration of use or any restrictions on the duration of use
Not to be taken for more than 2 months.
If the symptoms persist for more than 2 weeks during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted.
Any other information necessary for the safe use
Contra-indications
Hypersensitivity to the active substance.
Arterial hypertension.
Special warnings and precautions for use
The use in children under 12 years of age is not recommended because sufficient experience is not available.
If the symptoms worsen during the use of the medicinal product, a doctor or a qualified healthcare practitioner should be consulted.
Interactions with other medicinal products and other forms of interaction
None reported.
Pregnancy and lactation
Safety during pregnancy and lactation has not been established.
In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
Effects on ability to drive and use machines
No studies on the effect on the ability to drive and use machines have been performed.
Undesirable effects
Insomnia, irritability, tachycardia and headaches may occur. The frequency is not known.
Overdose
No case of overdose has been reported.’